Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Belgian biotech firm Confo Therapeutics raises $65 million
by Rowan Walrath
August 5, 2024
| A version of this story appeared in
Volume 102, Issue 24
Confo Therapeutics, a Belgian firm developing small molecules and antibodies that target G protein–coupled receptors, aims to start testing its drug candidates in humans with the help of $65 million in series B financing. The company plans to bring two medicines through Phase 1 clinical trials and get two more ready for the clinic, including molecules that target the receptor GPR75 for weight loss. Confo has previously partnered with Eli Lilly & Co. and Daiichi Sankyo.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter